Rhythm Pharmaceuticals reacquires rights to Imcivree in China for $6.3M
Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...
Nasdaq1mon
7 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
In the last three months, 7 analysts have published ratings on Rhythm Pharmaceuticals (NASDAQ:RYTM), offering a diverse range of perspectives from bullish to bearish. The following table ...
Yahoo Finance23d
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.70 per share a year ago.
ETF Daily News15d
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Target Price at $68.27
Rhythm Pharmaceuticals has a 52 week low of $35.17 and a 52 week high of $68.58. Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last released its earnings results on Wednesday, February ...